Bionano Genomics Announces Publication of a New Study Using OGM to Investigate Inversions that May Lead to Genetic Disorders
June 08 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome
mapping (OGM) solutions on the Saphyr® system and provider of
NxClinical™ software, the leading solution for visualization,
interpretation and reporting of genomic data, today announced the
publication of a multi-platform study using OGM in combination with
other cytogenetic technologies as a comprehensive strategy to
investigate inversions that may lead to genetic disorders.
This study, published in the journal Cell, analyzed inversions
using various methods, including OGM. The study reported that 80%
of the larger inversions that were detected were balanced and
affected twice as many nucleotides overall as copy number
variations (CNVs). The researchers noted that these inversions can
be associated with rare genomic rearrangements found in pediatric
autism, developmental delay, and epilepsy.
In the study, researchers analyzed 41 unrelated human samples
representing 729 inversion sites for recurrent inversion formation
using complementary genomic approaches, including single-cell
template strand sequencing (Strand-seq), long-read sequencing, and
OGM. Using this multi-platform method, researchers found 40
recurrent inversions that encompassed 0.6% of the genome, showing
that recurrent inversions can be co-localized with genomic disorder
regions.
Erik Holmlin, PhD, president and chief executive officer of
Bionano commented, “The most studied SVs have been CNVs because
they can be detected relatively easily by microarrays. This study
opens the door to a host of exploration of inversions and
illustrates that OGM has the potential to make large inversion
detection and analysis as routine as CNV analysis.”
This publication is available
at: https://pubmed.ncbi.nlm.nih.gov/35525246/
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view.
For more information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “can,” “potential,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the ability and utility of OGM and Saphyr® system to detect and
analyze large inversions, the potential for OGM to become part of
routine large inversion detection and analysis, and the correlation
of large inversions with genetic disorders. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
future study results to support those demonstrated in the paper
referenced in this press release; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024